Eosinophilic Esophagitis Market, by Drug Class (Corticosteroids: Budesonide {Jorveza and Off-label budesonide} and Fluticasone; Proton Pump Inhibitor (PPI): Omeprazole, Esomeprazole, and Others; and Late Stage Pipeline Drugs: Dupixent, APT-1011, Lirenteli

Eosinophilic Esophagitis Market, by Drug Class (Corticosteroids: Budesonide {Jorveza and Off-label budesonide} and Fluticasone; Proton Pump Inhibitor (PPI): Omeprazole, Esomeprazole, and Others; and Late Stage Pipeline Drugs: Dupixent, APT-1011, Lirentelimab (AK002), Cendakimab, Etrasimod, TAK-721, and Omilancor (BT-11)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Eosinophilic esophagitis is a chronic condition which is treated with the help of steroids and acid suppressants such as proton pump inhibitors. Steroids help control the inflammation. Topical steroids are administered as a inhaler or as a liquid. Oral steroids may be prescribed to treat people who have serious swallowing problems or weight loss. Proton pump inhibitors help with reflux symptoms and decrease inflammation.
Market Dynamics
Growing awareness regarding eosinophilic esophagitis leads to an increase in demand for treatment products. Thus, key market players are engaged in developing newer treatments and addressing the demand for EoE treatment products. For instance, Sanofi S.A. a global biopharmaceutical company engaged in conducting a phase 3 clinical trial for Dupixent (dupilumab) and is estimated to complete by 2023. Additionally, upcoming innovative products to improve the management of EoE are anticipated to drive the global market growth. For instance, in December 2021, Takeda Pharmaceutical Company Limited a Japanese multinational pharmaceutical company received a Complete Response Letter (CRL) for TAK-721 (budesonide oral suspension) from the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis. In June 2021, the U.S. FDA granted Orphan Drug Designation (ODD) for Etrasimod. Etrasimod had been investigated by Arena Pharmaceuticals, Inc. an American biopharmaceutical company. Moreover, an increase in the prevalence of eosinophilic esophagitis is likely boost the market growth. For instance, according to a study published in the Saudi Medical Journal in July 2018, eosinophilic esophagitis is an emerging disease and has an increasing incidence in children in Saudi Arabia.
Key features of the study:
This report provides an in-depth analysis of the global eosinophilic esophagitis market, market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global eosinophilic esophagitis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global eosinophilic esophagitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global eosinophilic esophagitis market.
Detailed Segmentation:
Global Eosinophilic Esophagitis Market, By Drug Class:
Corticosteroids
Budesonide
Jorveza
Off-label budesonide
Fluticasone
Proton Pump Inhibitor (PPI)
Omeprazole
Esomeprazole
Others
Late Stage Pipeline Drugs
Dupixent
APT-1011
Lirentelimab (AK002)
Cendakimab
Etrasimod
TAK-721
Omilancor (BT-11)
Global Eosinophilic Esophagitis Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Eosinophilic Esophagitis Market, By Region:
North America
By Drug Class
Corticosteroids
Budesonide
Jorveza
Off-label budesonide
Fluticasone
Proton Pump Inhibitor (PPI)
Omeprazole
Esomeprazole
Others
Late Stage Pipeline Drugs
Dupixent
APT-1011
Lirentelimab (AK002)
Cendakimab
Etrasimod
TAK-721
Omilancor (BT-11)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Drug Class
Corticosteroids
Budesonide
Jorveza
Off-label budesonide
Fluticasone
Proton Pump Inhibitor (PPI)
Omeprazole
Esomeprazole
Others
Late Stage Pipeline Drugs
Dupixent
APT-1011
Lirentelimab (AK002)
Cendakimab
Etrasimod
TAK-721
Omilancor (BT-11)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class
Corticosteroids
Budesonide
Jorveza
Off-label budesonide
Fluticasone
Proton Pump Inhibitor (PPI)
Omeprazole
Esomeprazole
Others
Late Stage Pipeline Drugs
Dupixent
APT-1011
Lirentelimab (AK002)
Cendakimab
Etrasimod
TAK-721
Omilancor (BT-11)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class
Corticosteroids
Budesonide
Jorveza
Off-label budesonide
Fluticasone
Proton Pump Inhibitor (PPI)
Omeprazole
Esomeprazole
Others
Late Stage Pipeline Drugs
Dupixent
APT-1011
Lirentelimab (AK002)
Cendakimab
Etrasimod
TAK-721
Omilancor (BT-11)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class
Corticosteroids
Budesonide
Jorveza
Off-label budesonide
Fluticasone
Proton Pump Inhibitor (PPI)
Omeprazole
Esomeprazole
Others
Late Stage Pipeline Drugs
Dupixent
APT-1011
Lirentelimab (AK002)
Cendakimab
Etrasimod
TAK-721
Omilancor (BT-11)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Drug Class
Corticosteroids
Budesonide
Jorveza
Off-label budesonide
Fluticasone
Proton Pump Inhibitor (PPI)
Omeprazole
Esomeprazole
Others
Late Stage Pipeline Drugs
Dupixent
APT-1011
Lirentelimab (AK002)
Cendakimab
Etrasimod
TAK-721
Omilancor (BT-11)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
GlaxoSmithKline plc*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Ellodi Pharmaceuticals
EsoCap AG
Teva Pharmaceutical Industries Ltd.
Cipla Limited
Sun Pharmaceutical Industries Limited
AstraZeneca Plc
Sanofi S.A.
Arena Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Revolo Biotherapeutics
Allakos Inc.
Bristol-Myers Squibb Co
Calypso Biotech
DBV Technologies
Landos Biopharma, Inc.
Glenmark Pharmaceuticals
Alkem Laboratories Ltd.
Quorum Innovations LLC
Dr. Falk Pharma GmbH
“*” marked represents similar segmentation in other categories in the respective section.